Qutenza (Capsaicin 8% patch)

Approved for Management of neuropathic pain associated with postherpetic neuralgia, Treatment of diabetic peripheral neuropathy of the feet. High-concentration capsaicin causes initial activation then prolonged desensitization of TRPV1-expressing nociceptive nerve fibers. Side effects, costs, interactions, manufacturer, and generic alternatives sourced from FDA labels, openFDA FAERS, and CMS…

Loading full data from Know Your Drugs Institute…